Johnson & Johnson (JNJ)
Johnson & Johnson wins first FDA approval for chemotherapy-free lung cancer treatment
Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has approved the combination of Rybrevant plus Lazcluze for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, the company said in a statement.
Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
The Highest Quality Dividend-Growth Healthcare Stocks
Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top quality stocks in the sector. Johnson & Johnson and Zoetis discussed as high-quality, fairly valued healthcare stocks with very different yields and growth rates.
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.
J&J to disclose support for $6.5 billion talc settlement
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.
Exclusive: J&J near disclosing support for talc settlement, sources say
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.
3 Blue-Chip Stocks to Buy on the Dip: August 2024
Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials, long histories of profitability and consistent records of dividend payments.
J&J has enough support from claimants for $6.5 billion talc settlement: report
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
J&J has enough support from claimants for $6.5 billion talc settlement - Bloomberg
Johnson & Johnson has cleared a key threshold of support for its proposed $6.5 billion settlement of tens of thousands of lawsuits alleging its baby powder and other talc products caused cancer, according to a Bloomberg report.
J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery
Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.
2 Healthcare Stocks to Buy Hand Over Fist in August
Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
